Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2003; 41(1): 52-53DOI: 10.1055/s-2003-36669 Leitlinien der DGVS © Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York Komplementäre Therapien Complementary TherapiesH. Matthes1 1Berlin Recommend Article Abstract Buy Article Full Text References Literatur 1 Rawsthorne P, Shanahan F, Cronin N C. et al . An international survey of the use and attitudes regarfing alternative medicine by patients with inflammatory bowel diesease. Am J Gastroenterol. 1999; 94 1298-1303 (III) 2 Eisenberg D, Kessler R C, Foster C. et al . Unconventional medicine in the United States: prevalence costs and patterns of use. N Engl J Med. 1993; 326 246-252 (III) 3 Hilsden R J, Scott C M, Verhoef M J. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol. 1998; 93 697-701 (III) 4 Moser G, Tillinger W, Sachs G. et al . Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res. 1996; 40 503-509 (III) 5 Verhoef M J, Scott C M, Hilsden R J. A multimethod research study on the use of complementary therapies among patients with inflammatory bowel disease. Altern Ther Health Med. 1998; 4 68-71 (III) 6 Moody G A, Eaden J A, Bhakta P. et al . The role of complementary medicine in European and Asian patients with inflammatory bowel disease. Public Health. 1998; 112 269-271 (III) 7 Pirotta M V, Cohen M M, Kotsirilos V. et al . Complementaries therapies: have they become accepted in general practice?. Med J Aust. 2000; 172 105-109 (III) 8 Bühring P. Ganzheitliche Therapie gewünscht. Deutsches Ärzteblatt. 2001; 20 A 1307 (IV) 9 Joos S, Maluche C, Maupai N. et al . Acupuncture and moxibustion in the treatment of active Crohn’s disease - a randomised controlled study. Forsch Komplementärmed. 2000; 43 (Ib) 10 NIH Consensus Conference . Acupuncture. JAMA. 1998; 280 1518-1524 (IV) 11 Gerhardt H, Seifert F, Buvari P. et al . Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol. 2001; 39 11-17 (Ib) 12 Rembacken B J, Snelling A M, Hawkey P M. et al . Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999; 354 635-639 (Ib) 13 Kruis W, Schutz E, Fric P. et al . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997; 11 853-858 (Ib) 14 Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001; 120 622-635 (IV) 15 Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?. Gastroenterology. 1999; 116 1246-1249 (IV) 16 Biancone L, Pallone F. Current treatment modalities in active Crohn’s disease. Ital J Gastroenterol Hepatol. 1999; 31 508-514 (IV) 17 Malchow H. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease. J Clin Gastroenterol. 1997; 25 653-658 (IIb) H. Matthes Berlin
